Transcend Therapeutics
Ben is the Co-Director of the Yale Program for Psychedelic Science and an Assistant Professor of Psychiatry at the Yale School of Medicine, one of the top-ranked psychiatry programs worldwide. He was the Principal Investigator on the first double-blind clinical trial investigating psilocybin in the treatment of OCD, and demonstrated early efficacy for esketamine. In 2021, Ben was the first recipient of a federal grant for clinical psychedelic research since 1967.
This person is not in any teams
This person is not in any offices
Transcend Therapeutics
1 followers
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.